Prague-based Pale Fire Capital SE added 639,162 shares of Teva in the third quarter. The overall position value increased by $16.53 million from the previous period.
TEL AVIV, Israel, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that S&P Global Ratings ("S&P") has upgraded Teva's long-term issuer credit rating to ‘BB+' from ‘BB', with a stable outlook, and that Moody's Ratings Agency ("Moody's") affirmed Teva's B1a rating and revised Teva's outlook to positive from stable. These upgrades mark another significant milestone in Teva's journey toward achieving investment-grade status.
Quarterly-filed Form 13Fs allow investors to track which stocks Wall Street's savviest money managers are buying and selling. Billionaire Stanley Druckenmiller dumped his fund's stakes in AI darlings Nvidia and Palantir -- and profit-taking may not explain the entire story.
Teva, the Israeli pharmaceutical giant, is reaching new heights, breaking the $30 mark. The rise in its share price reflects both the strengthening of its balance sheet and the rising sales of Austedo and Ajovy. So, sales of Ajovy totaled $169 million in Q3, up 22.5% year-on-year.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA - Get Free Report)'s stock price hit a new 52-week high during trading on Monday after Piper Sandler raised their price target on the stock from $30.00 to $40.00. Piper Sandler currently has an overweight rating on the stock. Teva Pharmaceutical Industries traded as high as $30.98 and last traded
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA - Get Free Report) CAO Amir Weiss sold 12,300 shares of the business's stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $30.20, for a total value of $371,460.00. Following the transaction, the chief accounting officer directly owned 5,650 shares
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA - Get Free Report) Director Roberto Mignone sold 77,400 shares of the firm's stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $30.24, for a total transaction of $2,340,576.00. Following the transaction, the director directly owned 367,600 shares of the company's stock,
REYKJAVIK, Iceland and TEL AVIV, Israel, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that they have reached a settlement and license agreement with Regeneron Pharmaceuticals Inc. concerning the launch of AVT06, Alvotech's proposed biosimilar to Eylea® (aflibercept) in the United States. The settlement grants a license entry date for AVT06 in the United States in the fourth quarter of 2026, or earlier under certain circumstances.
It's been another banner year on Wall Street, with the Dow Jones Industrial Average, S&P 500, and Nasdaq Composite, respectively, higher by 14%, 16%, and 20% year-to-date. Although I've been a net seller of stocks in 2025, I'm a long-term investor who intends to hold the majority of my 36 positions for years to come.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
